Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary.
Journal: Future oncology (London, England)
Published: December 08, 2025
Elranatamab: Mechanism of Action, Clinical, and Translational Science.
Journal: Clinical and translational science
Published: September 04, 2025
Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication.
Journal: Therapeutic advances in medical oncology
Published: December 17, 2024
Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia.
Journal: American journal of hematology
Published: November 11, 2024
A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients.
Journal: Clinical pharmacology and therapeutics
Published: September 20, 2024
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
Journal: Cancer chemotherapy and pharmacology
Published: October 27, 2022
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 02, 2021
Last Updated: 09/26/2026